NUMELVI (Atinvicitinib) – Post Launch Performance; USD 100 Mill in 2026?

This report is a Post-Launch appraisal of market performance of Numelvi (Atinvivitinib), the 3rd on Market and 1st, 2nd Generation JAK Inhibitor to be launched in US market. Numelvi is currently launched ONLY in US with final EU approval and commercial launch expected in H2′ 2006.

Disclosure / Disclaimer

Merck Animal Health has not reported / published stand alone revenue figure for Numelvi. Merck & Co. reports animal health as a single segment within Merck’s overall financials and does not break out individual brand / product sales. Numelvi was launched only very recently (spring 2026) for any quarterly disclosure to have captured it separately. This report therefore presents the full picture of what is documented — product performance data, competitive positioning, clinical evidence, and veterinary feedback — clearly distinguishing confirmed facts from analytical inference.

Launch timelines and commercial status

Merck Animal Health announced FDA approval of NUMELVI (atinvicitinib tablets) on February 25, 2026 — the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product was expected to be available at veterinary clinics and hospitals nationwide in spring 2026. WOAH

NUMELVI is currently the only JAK inhibitor approved for use in canine patients as young as 6 months and weighing up to 4.4 lb (2 kg). This means the product has been in commercial distribution for approximately 8–10 weeks as of today. No Merck quarterly earnings call has yet captured a full commercial quarter of Numelvi sales — the first data point will appear in Merck & Co.’s Q2 2026 results, expected in late July 2026.

Market Numelvi is entering — size and competitive dynamics

The canine allergic dermatitis / pruritus market is one of the most commercially significant and most contested product arenas in companion animal pharma. The competitive landscape as of May 2026:

Zenrelia achieved trailing four-quarter blockbuster status with over two million dogs treated. It has achieved use in over 50% of US clinics, with US JAK market share up 5 points versus Q4. Zenrelia holds over 50% share of the JAK market in Brazil, over 35% share in Japan, and high-teens to 30%+ JAK market share in key European markets.

This is the competitive wall Numelvi launched into — Elanco’s Zenrelia is already deeply established across 50%+ of US clinics, and Apoquel (Zoetis) remains the legacy market leader.

Numelvi’s clinical differentiation — what the evidence shows

According to data from Merck Animal Health, Numelvi’s active ingredient atinvicitinib is at least 10 times more selective for JAK1 than it is for JAK2, JAK3, and tyrosine kinase 2, and obstructs the effects of JAK1-dependent cytokines involved in inflammation and itch in allergic dermatitis. High selectivity for JAK1 can shrink interference with the beneficial immune functions of other JAKs, which can create a safety profile with proven efficiency.

A peer-reviewed study published in Veterinary Dermatology 2026 confirmed that the second-generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2–4 hours after dosing dogs in a canine interleukin-31 model. The 2–4 hour onset is a clinically meaningful differentiator — rapid itch relief is one of the most important factors driving veterinarian and owner satisfaction in dermatology products.

The six-month age eligibility is Numelvi’s single sharpest competitive edge. Both Apoquel and Zenrelia require dogs to be at least 12 months old. Numelvi is currently the only JAK inhibitor approved for use in canine patients as young as 6 months and weighing up to 4.4 lb (2 kg) — capturing a patient population previously unable to access JAK therapy and opening up the puppy-onset atopic dermatitis segment, which is clinically significant since early intervention can prevent chronic skin damage.

Veterinary and professional feedback

Christine McKinney, DVM, DACVD, Senior Professional Services Veterinarian at Merck Animal Health, stated: “With more than 70 years of innovation and commitment to animal health, we are confident that NUMELVI will offer veterinary professionals a groundbreaking, first-of-its-kind solution aimed at improving the health and well-being of dogs — from as young as six months to mature dogs.

From the independent clinical and veterinary community — the Alford Avenue Veterinary Hospital analysis (published April 23, 2026, the most detailed independent clinical commentary available) positions Numelvi as “a welcome addition to the canine atopic dermatitis toolkit” particularly for younger dogs and small-breed patients previously unable to use JAK therapy.

Peer-reviewed publication context: A study published in Veterinary Dermatology 2026 by Kowalski and Schuette confirms atinvicitinib is a potent and highly selective inhibitor of JAK1. This peer-reviewed support in a respected specialty journal within weeks of launch is a positive signal — it provides dermatology specialists with the academic validation needed to prescribe with confidence.

Known clinical caution: NUMELVI may increase susceptibility to opportunistic infections, including demodicosis and interdigital furunculosis. Consider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis. This is a class-effect caution shared with all JAK inhibitors and is not unique to Numelvi, but dermatology-specialist veterinarians will apply it as a selection criterion — patients with demodicosis history will be steered toward Cytopoint (injectable anti-IL-31) rather than any JAK inhibitor.

Field study limitation: The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days. This is a meaningful label limitation that attentive veterinarians will note — long-term safety in the real-world population remains to be established. Zenrelia and Apoquel both have multi-year real-world safety datasets, which gives them an advantage with cautious prescribers.

EU and international status

Numelvi received a positive EU opinion from the Committee for Veterinary Medicinal Products (CVMP), with the European Commission expected to make a final decision during Q3 2025. EU marketing authorization was therefore expected by late 2025/early 2026. EU commercial launch timing has not been separately announced by Merck Animal Health.

Competitive intelligence — the Zenrelia benchmark

The most useful competitive benchmark for Numelvi’s expected trajectory is Zenrelia’s launch performance, which is well documented:

Over half a million dogs around the world had been treated with Zenrelia by September 2025 — just one year after FDA approval in September 2024. Elanco noted it was inspired by the positive and growing feedback from dermatologists, general practice veterinarians, and pet owners.

Elanco positioned Zenrelia at launch as a “differentiated second-to-market product in canine dermatology” targeting the 17M addressable market in US canine dermatology. In a head-to-head clinical study, 77% of Zenrelia-treated dogs achieved PVAS less than 2 (near-complete itch control) compared to 53% of Apoquel-treated dogs at an additional endpoint — a significant clinical differentiation claim.

Numelvi enters as third-to-market in the JAK inhibitor category. The “third-to-market archetype” is challenging — Elanco itself noted this difficulty with Credelio Quattro (which was third to market in parasiticides) but succeeded by targeting underserved segments. For Numelvi, the 6-month age eligibility is that underserved segment. Success will depend on how effectively Merck’s sales force penetrates the specific puppy and small-breed patient population.

Assessment summary

Bottom line: Numelvi is a scientifically well-differentiated product with a genuine clinical niche — but it is too early (approximately 8–10 weeks in commercial distribution) for any meaningful financial performance data to exist in the public domain. The first hard commercial signal will come from Merck & Co.’s Q2 2026 earnings in late July. The product’s long-term success will be determined by whether the 6-month age eligibility proves as commercially significant as the clinical gap it fills suggests — and whether Merck’s sales force can convert dermatology referral networks before Zenrelia’s 50%+ clinic penetration becomes an insurmountable incumbent advantage and whether NUMELVI can achieve blockbuster status in 2026, the first year of its launch as achieved by Zenrelia recently and Apoquel, earlier.